Abstract: A gas is fed, so as to cause a gas flow to occur from a lower opening of a bearing hole of a sleeve 6 in an outward direction of an annular portion 12a of a rotor hub 12 via a radial gap 50 and an upper opening of the bearing hole, thereby lifting a rotor section 10. In a condition where the rotor section 10 is lifted, the magnitude of run-out synchronized with the rotation of the rotor section 10 is measured by using a displacement gauge 40. Then, based on the magnitude of run-out synchronized with the rotation, the run-out of the rotor section 10 is adjusted.

Abstract: A gas is fed, so as to cause a gas flow to occur from a lower opening of a bearing hole of a sleeve 6 in an outward direction of an annular portion 12a of a rotor hub 12 via a radial gap 50 and an upper opening of the bearing hole, thereby lifting a rotor section 10. In a condition where the rotor section 10 is lifted, the magnitude of run-out synchronized with the rotation of the rotor section 10 is measured by using a displacement gauge 40. Then, based on the magnitude of run-out synchronized with the rotation, the run-out of the rotor section 10 is adjusted.

Abstract: A hold-transfer system for extraction containers has a main body and a cassette detachable from the main body. The cassette has holding devices for holding extraction containers in an upright position, an endless traveling member carrying the holding devices arranged in a row, and a driving rotor and a driven rotor engaging the endless traveling member about perimeters thereof. The endless traveling member has rotatable support member for rotatably supporting the holding devices with lower portions of the holding devices protruding below the rotatable support members and accessible from beneath the cassette. The main body has a driving motor for driving the driving rotor and an identifying device, installed at a reading position relative to a specified position for an extraction, for identifying an identification mark associated with one of the extraction containers.

Abstract: This invention relates to pyridazinone derivatives of the general formula: ##STR1## [wherein R.sup.1 stands for a hydrogen atom or a lower alkyl group; R.sup.2 for a hydrogen atom or a lower alkyl group; and A for (i) a ring selected from a benzene ring, a furan ring, a thiophene ring and a pyridine ring (on which ring 1-3 substituents or atoms selected from amino groups, nitro groups, lower alkanoylamino groups, hydroxyl groups, lower alkanoyloxy groups, sulfamoyl groups and halogen atoms may be present), or (ii) a grouping of the formula: ##STR2## (wherein R.sup.3 stands for a hydrogen atom, a lower alkyl group, a phenyl(lower)alkyl, a hydroxyphenyl(lower)alkyl group, a lower alkylmercapto(lower)alkyl group, a benzylmercapto(lower)alkyl group, a guanidino(lower)alkyl group, a nitroguanidino(lower)alkyl group, an indolyl(lower)alkyl group, a carbamoyl(lower)alkyl group or a carboxy(lower)alkyl group, R.sup.4 for a hydrogen atom or a lower alkyl group, R.sup.

Abstract: Disclosed herein is an antihypertensive preparation containing, as an active component, a novel quinazoline derivative represented by the following general formula or a salt thereof: ##STR1## wherein R.sup.100 means a hydrogen atom or methoxy group, R.sup.200 and R.sup.300 denote individually a hydrogen atom or lower alkoxy group, R.sup.400 is a hydrogen atom or amino group, l stands for 2 or 3, and Het is a specific hetero ring group.

Abstract: This invention relates to pyridazinone derivatives of the general formula: ##STR1## [wherein R.sup.1 stands for a hydrogen atom or a lower alkyl group; R.sup.2 for a hydrogen atom or a lower alkyl group; and A for (i) a ring selected from a benzene ring, a furan ring, a thiophene ring and a pyridine ring (on which ring 1-3 substituents or atoms selected from amino groups, nitro groups, lower alkanoylamino groups, hydroxyl groups, lower alkanoyloxy groups, sulfamoyl groups and halogen atoms may be present), or (ii) a grouping of the formula: ##STR2## (wherein R.sup.3 stands for a hydrogen atom, a lower alkyl group, a phenyl(lower)alkyl, a hydroxyphenyl(lower)alkyl group, a lower alkylmercapto(lower)alkyl group, a benzylmercapto(lower)alkyl group, a guanidino(lower)alkyl group, a nitroguanidino(lower)alkyl group, an indolyl(lower)alkyl group, a carbamoyl(lower)alkyl group or a carboxy(lower)alkyl group, R.sup.4 for a hydrogen atom or a lower alkyl group, R.sup.

Abstract: This invention relates to benzothiazepine derivatives of the general formula ##STR1## where K is hydrogen or a --CH.sub.2 COOR.sub.2 group where R.sub.2 is hydrogen or a lower alkyl group, Z is hydrogen or phenyl except when both K and Z are hydrogen, and Y is hydrogen, a --CHR.sub.3 --COOR.sub.1 group, an alkanoyl group or a --COO(CH.sub.2).sub.n R.sub.4 group where R.sub.1 is hydrogen or a lower alkyl group, R.sub.3 is hydrogen, an alkyl group, an alkylphenyl group or an aryl-lower alkyl group, R.sub.4 is an aryl group and n is a whole number of 1 to 10, and to their methods of preparation.The benzothiazepine derivatives of this invention, including their salts, have a powerful inhibitory effect on the angiotensin converting enzyme and exert a marked depressor effect in such models of hypertension as spontaneously occurring hypertensive rats and the like, so that they are useful as drugs for the treatment of hypertension and other cardiovascular diseases.

Abstract: 6-(Substituted phenyl)-4,5-dihydro-3(2H)-pyridazinone compounds possessing strong platelet aggregation inhibiting activity and blood pressure depressing activity, having the general formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen, lower alkyl, lower alkylthio or the grouping R.sup.5 --NH-- where R.sup.5 is lower alkyl; R.sup.3 is phenyl, pyridyl, benzyl, lower alkyl or a substituted phenyl group carrying at any desired position on the benzene ring thereof the grouping: ##STR2## where R.sup.1 has the same meaning as given above; R.sup.4 is hydrogen or halogen; n is 0 or 1; and when both R.sup.2 and R.sup.3 are lower alkyl groups, R.sup.2 and R.sup.3 may be combined together with the bridging member ##STR3## between them to form the structure: ##STR4## where m is 2 or 3, as well as physiologically acceptable acid-addition salts thereof, and processes for preparing them.

Abstract: 6-(Substituted phenyl)-4,5-dihydro-3(2H)-pyridazinone compounds possessing strong platelet aggregation inhibiting activity and blood pressure depressing activity, having the general formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen, lower alkyl, lower alkylthio or the grouping R.sup.5 --NH-- where R.sup.5 is lower alkyl; R.sup.3 is phenyl, pyridyl, benzyl, lower alkyl or a substituted phenyl group carrying at any desired position on the benzene ring thereof the grouping: ##STR2## where R.sup.1 has the same meaning as given above; R.sup.4 is hydrogen or halogen; n is 0 or 1; and when both R.sup.2 and R.sup.3 are lower alkyl groups, R.sup.2 and R.sup.3 may be combined together with the bridging member ##STR3## where m is 2 or 3, as well as physiologically acceptable acid-addition salts thereof, and processes for preparing them.